The multi-factorial nature of clinical multidrug resistance in cancer
Curative cancer therapy remains a major challenge particularly in cancers displaying
multidrug resistance (MDR). The MDR phenotype is characterized by cross-resistance to a …
multidrug resistance (MDR). The MDR phenotype is characterized by cross-resistance to a …
[HTML][HTML] ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour …
Background Cancers with a defective DNA mismatch repair (dMMR) system contain
thousands of mutations most frequently located in monomorphic microsatellites and are …
thousands of mutations most frequently located in monomorphic microsatellites and are …
[HTML][HTML] Quantitative proteomics of the cancer cell line encyclopedia
Proteins are essential agents of biological processes. To date, large-scale profiling of cell
line collections including the Cancer Cell Line Encyclopedia (CCLE) has focused primarily …
line collections including the Cancer Cell Line Encyclopedia (CCLE) has focused primarily …
[HTML][HTML] FDA-approved and emerging next generation predictive biomarkers for immune checkpoint inhibitors in cancer patients
Y Wang, Z Tong, W Zhang, W Zhang, A Buzdin… - Frontiers in …, 2021 - frontiersin.org
A patient's response to immune checkpoint inhibitors (ICIs) is a complex quantitative trait,
and determined by multiple intrinsic and extrinsic factors. Three currently FDA-approved …
and determined by multiple intrinsic and extrinsic factors. Three currently FDA-approved …
[HTML][HTML] Predictive biomarkers for checkpoint inhibitor-based immunotherapy in hepatocellular carcinoma: where do we stand?
A Rizzo, AD Ricci, A Di Federico, G Frega… - Frontiers in …, 2021 - frontiersin.org
Hepatocellular carcinoma (HCC) remains the sixth most commonly diagnosed malignancy
worldwide, still representing an important cause of cancer-related death. Over the next few …
worldwide, still representing an important cause of cancer-related death. Over the next few …
[HTML][HTML] Mismatch repair pathway, genome stability and cancer
The acquisition of genomic instability is one of the key characteristics of the cancer cell, and
microsatellite instability (MSI) is an important segment of this phenomenon. This review aims …
microsatellite instability (MSI) is an important segment of this phenomenon. This review aims …
[HTML][HTML] Microsatellite instability in Gastric Cancer: Between lights and shadows
Gastric cancer (GC) represents an important contributor to the global burden of cancer,
being one of the most common and deadly malignancies worldwide. According to TCGA and …
being one of the most common and deadly malignancies worldwide. According to TCGA and …
Which role for predictors of response to immune checkpoint inhibitors in hepatocellular carcinoma?
A Rizzo, A Cusmai, G Gadaleta-Caldarola… - Expert review of …, 2022 - Taylor & Francis
Introduction Hepatocellular carcinoma (HCC) remains a frequently diagnosed malignancy
worldwide, still representing an important cause of cancer-related death. Recent years have …
worldwide, still representing an important cause of cancer-related death. Recent years have …
[HTML][HTML] POLE/POLD1 mutation and tumor immunotherapy
X Ma, L Dong, X Liu, K Ou, L Yang - Journal of Experimental & Clinical …, 2022 - Springer
POLE and POLD1 encode the catalytic and proofreading subunits of DNA polymerase ε and
polymerase δ, and play important roles in DNA replication and proofreading. POLE/POLD1 …
polymerase δ, and play important roles in DNA replication and proofreading. POLE/POLD1 …
[HTML][HTML] Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives
JY Sun, D Zhang, S Wu, M Xu, X Zhou, XJ Lu, J Ji - Biomarker Research, 2020 - Springer
Abstract PD-1/PD-L1 blockade therapy is a promising cancer treatment strategy, which has
revolutionized the treatment landscape of malignancies. Over the last decade, PD-1/PD-L1 …
revolutionized the treatment landscape of malignancies. Over the last decade, PD-1/PD-L1 …